Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in Active Lupus Nephritis
NCT05268289Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 2 trial of Iptacopan in lupus nephritis (LN), sponsored by Novartis. Started Aug 2022; status: terminated.
02
Drugs
Iptacopan
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05268289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05268289.